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Background: Atrial ﬁbrillation (AF) often occurs in the acute phase of heart failure (AHF), and is usually
associated with a rapid ventricular response. No drug with proven efﬁcacy in the treatment of AF in the
setting of AHF has been approved in Japan. We prospectively investigated the efﬁcacy and safety of
intravenous amiodarone injection in patients with AHF using a uniﬁed protocol.
Methods: The study included 20 consecutive patients (15 males; mean age, 6778 years) admitted for
AHF accompanied by AF with rapid ventricular response (mean, 137715 beats/min). Eleven patients had
recent-onset/transient/paroxysmal AF, and the other 9 had persistent/long-standing persistent AF.
Amiodarone injection was administered for 24 h under continuous ECG monitoring according to a
protocol used for ventricular tachyarrhythmias in Japan.
Results: In 10 of the 11 patients with recent-onset/transient/paroxysmal AF, AF was converted to sinus
rhythm at a mean of 5.8 h after initiation of intravenous amiodarone. In these patients, the heart rate
during AF was reduced from 132715 to 101720 beats/min (Po0.01). Five patients experienced a
recurrence of AF during amiodarone administration, with a heart rate of 95718 beats/min during AF,
which was again converted to sinus rhythm in the course of amiodarone administration. AF was not
converted to sinus rhythm in the remaining recent-onset/transient/paroxysmal AF patient and the
9 patients with persistent/long-standing persistent AF, but a signiﬁcant reduction in heart rate was noted
from 6 h after amiodarone initiation and was maintained during the administration period
(141715 beats/min at baseline and 101720 at 24 h after administration, Po0.01). No severe adverse
events were noted during the intravenous administration of amiodarone.
Conclusions: Intravenous amiodarone seems to be useful and tolerable in the treatment of AF with rapid
ventricular response in Japanese patients with AHF while showing rhythm and rate control effects.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Atrial ﬁbrillation (AF) is observed in 10–30% of patients with
symptomatic heart failure, and the incidence is increased to about
50% in New York Heart Association (NYHA) class IV patients with
severely decompensated hear failure [1,2]. The Studies of Left
Ventricular Dysfunction (SOLVD) trial evaluated moderate or
severe heart failure patients with NYHA class II and III symptoms
and found that all-cause mortality, deaths from heart failure, and
the frequency of hospitalization were increased by concomitant AF
[3]. Moreover, all-cause mortality was increased by about 35% in
patients with heart failure complicated by AF as compared to that
in non-complicated heart failure patients [1].
AF aggravates hemodynamics and cardiac function by causing a
rapid ventricular rate, loss of atrial kick, irregular RR interval, and
loss of physiological atrioventricular synchrony [4]. When hemo-
dynamics are exacerbated, cardiac function declines further and
enhances the persistence of AF, forming a vicious cycle. When AF
occurs in the acute phase of heart failure (AHF), the heart rate
rapidly increases and blood pressure decreases, resulting in
cardiogenic shock in some patients. This situation necessitates
emergency action, but electrical cardioversion done in such a
setting is often ineffective, and even if AF is terminated, recurrence
of arrhythmia is immediate in many cases. In terms of acute phase
drug therapy for AF complicating AHF, no drug with proven
efﬁcacy and safety has been approved in Japan, and digoxin has
been used empirically in such cases. For rate control during AF
with AHF, a beta-blocker and additional administration of digoxin
are recommended as Class I pharmacological therapy in the
Japanese Circulation Society (JCS 2010) Guidelines and the Eur-
opean Society of Cardiology (ESC) Guidelines [5]. However, in
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hemodynamically unstable patients with AHF and low left ven-
tricular function, the use of sufﬁcient beta-blocker doses is often
difﬁcult due to the negative inotropic effect of this drug class.
Although amiodarone is recommended as a beta-blocker alter-
native in the JCS 2010 Guidelines, the method of administration is
not speciﬁed. In 2010, oral amiodarone was approved for AF
accompanied by left ventricular dysfunction in Japan. Oral amio-
darone seems to be effective in AF patients with AHF; however, its
effect is not immediate and oral intake is problematic in some
severely unstable patients. Thus, intravenous administration is
desirable, as recommended by Guidelines in Western countries.
In japan, intravenous amiodarone was approved for the treat-
ment of ventricular tachycardia (VT) and ventricular ﬁbrillation
(VF), but not for AF even in patients with AHF. The use of
intravenous amiodarone was reportedly safe even in the presence
of severe organic heart diseases [6]. However, only a few pro-
spective studies have investigated its effects on rhythm and rate
control and its safety for the acute phase treatment of AF
complicating severe heart failure. In this study, we prospectively
investigated the safety and efﬁcacy of intravenous amiodarone,
including the resolution of AF, maintenance of sinus rhythm, and
rate control during AF, as an acute phase treatment of AF in
patients with AHF using a uniﬁed protocol.
2. Material and methods
This study was performed after approval by the Ethics Com-
mittee of Hirosaki University Graduate School of Medicine (No.
2011-128). Written informed consent was obtained from all
patients before the study.
2.1. Study patients
This study included the 20 consecutive patients who were
admitted to our hospital between October 2011 and December
2012 for AHF with NYHA class III and IV symptoms complicated by
AF. There were 15 male and 5 female patients, and their mean age
was 6778 years. Eleven patients were considered to have recent-
onset, transient, or paroxysmal AF and the remaining 9 to have
persistent or long-standing persistent AF based on clinical
histories including ECG ﬁndings and/or subjective symptoms
before and after hospitalization. Recent-onset/transient AF was
deﬁned as AF that ﬁrst appeared after hospitalization. Paroxysmal
AF was deﬁned as AF that spontaneously terminated within 7 days
after initiation, and persistent AF was deﬁned as sustained AF
lasting beyond 7 days. Long-standing persistent AF was deﬁned as
sustained AF lasting for 41 year before hospitalization. All
patients with persistent or long-standing AF had received long-
term warfarin therapy until their admission for AHF. The clinical
characteristics and underlying heart diseases of the study popula-
tion are shown in Table 1. The left ventricular ejection fraction
(LVEF) measured by echocardiography at admission was
33.677.8% (range, 20.8–46.7). Blood tests showed a plasma brain
natriuretic peptide (BNP) level of 955 pg/ml (range, 43–4301).
Patients with marked sinus bradycardia or conduction system
disturbance before the development of AF and those with severe
respiratory failure were excluded from this study. Patients with an
unknown time of AF onset and those who were not administered
warfarin were also excluded. There were no patients with the
Wolff-Parkinson-White syndrome.
AHF was managed by standard methods including intravenous
administration of diuretics and nitrates according to the Guide-
lines for Treatment of Acute Heart Failure (JCS 2011). No patient
was administered a beta-blocker or digoxin. In patients with acute
coronary syndrome, percutaneous coronary intervention and
intra-aortic balloon pumping were performed. Continuous heparin
administration was initiated on admission or at the onset of AF in
all patients as an antithrombotic therapy. When oral administra-
tion became possible, heparin was switched to oral warfarin or
dabigatran after consideration of liver and renal functioning.
2.2. Administration of amiodarone
After heparin sodium was administered to obtain an activated
partial prothrombin time ratio between 1.5 and 2.0 times the
normal value, intravenous amiodarone was continuously adminis-
tered for 24 h according to the protocol recommended for the
treatment of VT/VF in Japan. The protocol consisted of the initial
bolus administration of 125 mg for 10 min and loading dose
administration at 48 mg/h for the subsequent 6 h followed by
maintenance dose administration at 24.8 mg/h. Using a bedside
Table 1
Clinical proﬁles of the study patients.
Recent-onset/transient/paroxysmalAF Persistent/long-standing AF P value
Number of patients 11 9
Age (years) 6976 63710 0.0978
Gender(M/F) 10/1 5/4 0.1273
Underlying heart disease
Acute MI 4 0
Previous MI 2 2
Valvular disease 2 5
TIC 1 2
Acute myocarditis 1 0
Takotsubo cardiomyopathy 1 0
Hypertension 10 7
Diabetes mellitus 5 3
LVEF (%) 3378 3478 0.8431
Plasma BNP level (pg/mL), (median [range]) 559(43–4301) 779(249–2236) 0.7791
Medications before admission
Warfarin 5 9
Aspirin 4 3
Beta blocker 3 3
Calcium antagonist 1 0
Digoxin 0 1
Antiarrhythmic drugs 3 0
AF, atrial ﬁbrillation; BNP, brain natriuretic peptide; MI, myocardial infarction; LVEF, left ventricular ejection fraction and TIC, tachycardia-
induced cardiomyopathy.
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ECG monitor (Life Scope TR, Nihon Kohden, Tokyo, Japan), cardiac
rhythm, non-invasive cuff blood pressure, and heart rate were
continuously recorded for 24 h from the initiation of amiodarone
administration. The mean heart rate during AF was calculated
every minute by averaging the previous 8 heartbeats. A 12-lead
ECG was recorded before and 24 h after amiodarone administra-
tion, as well as whenever necessary. At the completion of amio-
darone administration, venous blood samples were obtained to
measure plasma amiodarone levels. Amiodarone infusion was
continued for 24 h as a rule, even when sinus rhythm resumed
after initiation.
2.3. Statistical analysis
All data are expressed as the mean7one standard deviation
except for the plasma BNP level, which is expressed as the median
value and range. Chronotropic changes in heart rate and blood
pressure were analyzed using one-way ANOVA, followed by the
Tukey–Kramer test for post hoc analysis. The unpaired t-test was
used to analyze differences in mean heart rate, blood pressure, and
ECG ﬁndings. Fisher's exact test was used for comparisons of
categorical parameters. A two-sided P value o0.05 was consid-
ered statistically signiﬁcant. All statistical analyses were per-
formed using JMP software version 10.0 (SAS Institute, Cary,
North Carolina).
3. Results
Before amiodarone administration, the heart rate in the overall
patient group was 137715 beats/min. However, the heart rate
before amiodarone administration was signiﬁcantly greater in the
9 patients with persistent/long-standing persistent AF than in the
11 patients with recent-onset/transient/paroxysmal AF (145711
versus 130716 beats/min, Po0.05).
3.1. Effect of intravenous amiodarone in recent-onset/transient/
paroxysmal AF
The chronological change in mean heart rate during AF or sinus
rhythm obtained during intravenous amiodarone administration is
shown in Fig. 1. In 10 of the 11 patients (91%) with recent-onset/
transient/paroxysmal AF, AF was converted to sinus rhythm
at a mean of 5.8 h (3457311 mins) after the initiation of intrave-
nous amiodarone. The times following amiodarone initiation
at which AF conversion occurred are indicated by arrows for
these 10 patients. The mean heart rate in these patients decreased
signiﬁcantly from 132715 beats/min before amiodarone to
101720 beats/min just before AF termination (Po0.01), which
is indicative of the rate and rhythm control effects of intravenous
amiodarone (Fig. 2). In 5 patients, AF recurred 1477 h after the
initiation of amiodarone, but the heart rate during recurring AF
remained decreased at 95718 beats/min. In these 5 patients, AF
was again converted to sinus rhythm during amiodarone admin-
istration at 2.6 h (154777 min) after recurrence. In the 1 remain-
ing patient, AF persisted for 424 h while the heart rate was
decreased from 111 to 75 beats/min.
3.2. Effect of intravenous amiodarone in persistent/long-standing
persistent AF
The chronological change in mean heart rate after the initiation
of intravenous amiodarone is shown in Fig. 3. AF was not
converted to sinus rhythm by 24-h intravenous amiodarone
administration in these 9 patients. However, a signiﬁcant decrease
in heart rate was noted from 5 h after administration. At 24 h after
administration, the heart rate was decreased from 145711 beats/
min before administration to 104718 beats/min (Po0.01) (Fig. 2,
left panel).
3.3. Comparison of mean heart rate between the groups with and
without AF conversion to sinus rhythm
The right panel of Fig. 2 shows a comparison of the changes in
mean heart rate after the initiation of intravenous amiodarone
between patients with (n¼10) and without AF conversion to sinus
rhythm (n¼10) within 24 h after amiodarone initiation. In the 10
patients without AF conversion, a signiﬁcant reduction in heart
rate was noted from 6 h after administration and was maintained
during administration (141715 beats/min at baseline and
101720 at 24 h after administration, Po0.01). There was no
signiﬁcant difference between the mean heart rate just before AF
termination in patients with AF conversion and the mean heart
rate at 24 h after amiodarone in patients without AF conversion.
3.4. Blood pressure, plasma level, ECG parameters, and adverse
effects
In all patients, blood pressure remained stable during amiodar-
one administration (Fig. 4). Exacerbation of heart failure during
amiodarone administration was not noted in any of the patients.
None of the patients required urgent electrical cardioversion for AF
because of hemodynamic collapse.
The plasma amiodarone level at 24 h after administration was
8817409 ng/ml, and the desethylamiodarone level was less than
100 ng/ml in all patients. On ECG, the QRS width was 112718 ms
before amiodarone administration and 112719 ms at 24 h after
amiodarone (P¼NS). The QT interval was 462730 ms before and
475741 ms after amiodarone (P¼NS).
No severe adverse events, such as low systolic blood pressure
o60 mmHg, marked bradycardia o45 beats/min, and ventricular
tachycardia, were noted during and after intravenous amiodarone.
3.5. Follow-up
In 16 patients, intravenous amiodarone was safely switched to
oral amiodarone at doses of 200–400 mg/day. In the remaining
4 patients, carvedilol (2.5 mg/day) was administered after intra-
venous amiodarone.
In 6 of the 10 patients without AF conversion to sinus rhythm
by intravenous amiodarone, AF was converted to sinus rhythm at a
mean of 78 days (range, 3–214) after oral amiodarone administra-
tion. In 5 of these patients as well as in 5 of the 10 patients who
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Fig. 1. Chronological changes in mean heart rate during atrial ﬁbrillation (AF) or
sinus rhythm (SR) after intravenous amiodarone in 11 patients with recent-onset/
transient/paroxysmal AF.
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converted to sinus rhythm during intravenous amiodarone admin-
istration, oral amiodarone at doses of 50–200 mg/day was con-
tinued. Carvedilol (range, 1.25–10 mg/day, n¼11) or bisoprolol
(range, 1.25–7.5 mg/day, n¼3) were continued in combination
with or without oral amiodarone.
4. Discussion
4.1. Major ﬁndings
Using the same administration protocol as that recommended
for VT/VF treatment in Japan, the present study demonstrated that
AF was converted to sinus rhythm at a mean of 5.8 h after the
initiation of amiodarone in 91% of patients with recent-onset/
transient/paroxysmal AF following heart rate reduction during AF.
Although AF was not converted in any of the patients with
persistent/long-standing persistent AF, amiodarone effectively
reduced the heart rate in all patients to a mean of 104 beats/
min. Blood pressure remained stable during amiodarone admin-
istration and no serious adverse effects such as marked blood
pressure decrease and bradycardia were observed. Thus, intrave-
nous amiodarone administration is effective for both rhythm and
rate control in AF complicated by AHF.
4.2. Treatment of AF complicated by AHF
AHF is often complicated by AF with rapid ventricular response,
which deteriorates heart failure by forming a vicious cycle. For the
pharmacological treatment of AHF, the Japanese Guidelines for
Treatment of Acute Heart Failure (JCS 2011) recommended the use
of diuretics such as furosemide and carperitide and vasodilators
such as nitrates and nicorandil for most cases, and sympathomi-
metic amine and other inotropic drugs when indicated in some
cases, in addition to the elimination of precipitating factors for
AHF and treatment of underlying diseases such as myocardial
ischemia. For the treatment of AF with rapid ventricular response
in this setting, digoxin, non-dihydropyridine calcium channel
antagonists such as verapamil and diltiazem, and beta-blockers
are recommended. Digoxin has long been used for the treatment
of not only chronic heart failure but also AF. In the setting of AHF,
however, there has been no evidence that digoxin effectively
controls AF. Since digitalis does not block excessive exercise-
induced tachycardia, its heart rate-reducing effect during AF seems
to be limited in AHF, where sympathetic nerve activity is generally
enhanced. The use of non-dihydropyridine calcium channel
antagonists and beta-blockers in patients with AHF is often
difﬁcult because of their negative inotropic effect. Class I antiar-
rhythmic drugs were proven to be deleterious in patients with
heart failure and reduced left ventricular function.
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Fig. 2. Rate control effect of intravenous amiodarone. Left panel: effect of amiodarone in patient groups with recent-onset/transient/paroxysmal atrial ﬁbrillation (AF)
(n¼11) and with persistent/long-standing persistent AF (n¼9). Right panel: effect of amiodarone in the patient groups with (n¼10) and without conversion of AF to sinus
rhythm (SR) (n¼10) after drug administration.
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Fig. 3. Chronological changes in mean heart rate during atrial ﬁbrillation (AF) after
intravenous amiodarone in 9 patients with persistent/long-standing persistent AF.
*Po0.05 versus baseline heart rate.
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Fig. 4. Chronological changes in systolic/diastolic blood pressures after intravenous
amiodarone. Data are shown for patients with and without conversion of atrial
ﬁbrillation (AF) to sinus rhythm (SR).
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Amiodarone is the drug recommended for rate control of AF
with rapid ventricular response in patients with chronic heart
failure in whom beta-blockers cannot be administered. Amiodar-
one shows little negative inotropic effect and can be used in
patients with reduced left ventricular function. The recent Eur-
opean Society of Cardiology (ESC) Guideline for the diagnosis and
treatment of acute and chronic heart failure 2012 [7] recom-
mended anticoagulation, electrical cardioversion in cases when
urgent restoration of sinus rhythm is required, administration of
amiodarone for pharmacological cardioversion in cases of AF
duration o48 h, and digitalis in patients with acute heart failure
and AF with a rapid ventricular response. In Japan, oral amiodar-
one is approved for treating AF in patients with heart failure and
left ventricular dysfunction, but the intravenous regimen is not.
The Japanese Guidelines for treatment of acute heart failure
described the effectiveness of oral amiodarone for both rhythm
and rate control in patients with acute heart failure and AF. Thus,
in Japan, the efﬁcacy and safety of intravenous amiodarone has
been never examined in patients with AHF complicated by AF with
a rapid ventricular rate.
4.3. Effect of intravenous amiodarone
In this study, we administered amiodarone intravenously in
patients with AHF complicated by AF. All patients showed rapid
ventricular response during AF for which rate or rhythm control
was required. In patients with recent-onset/transient/paroxysmal
AF, intravenous amiodarone was initiated after heparin adminis-
tration. Amiodarone could be initiated in patients with persistent/
long-standing persistent AF who were already administered war-
farin at the time of admission. Our hypothesis was that in patients
with recent-onset/transient/paroxysmal AF, intravenous amiodar-
one shows rhythm control effects, and in those with persistent/
long-standing persistent AF, it shows rate control effects. Because
the intravenous dose for AF has not been tested in Japan, we used
the same protocol as that used for VT/VF treatment, consisting of
the initial bolus administration of 125 mg for 10 min and loading
dose administration at 48 mg/h for the subsequent 6 h followed by
maintenance dose administration at 24.8 mg/h. The literature on
the dosing of intravenous amiodarone showed that the bolus dose
ranged from 3 to 7 mg/kg body weight and continuous infusion
dose ranged from 900 to 3000 mg/day. Both these bolus and
continuous infusion doses are much higher than those used in
the present study.
Intravenous amiodarone converted recent-onset/transient/par-
oxysmal AF to sinus rhythm at a mean of 5.8 h after administration
in 91% of patients. Further, this was associated with a reduction of
the heart rate during AF just before AF termination. Thus, intra-
venous amiodarone was found to be effective for both rate and
rhythm control in patients with AHF and recent-onset/transient/
paroxysmal AF. The rate of conversion to sinus rhythm by
amiodarone bolus injection and continuous infusion in newly
developed AF has been reported to be 55–95% at 24 h of admin-
istration [8]. It was shown that only a dose 41500 mg/day is
superior to placebo in converting recent-onset AF to sinus rhythm.
The total dose used in the present study (875 mg/day) was lower
than those in previous reports, but the conversion rate to sinus
rhythm was equivalent to that previously reported. The ESC
Guidelines for the management of AF [5] recommend the admin-
istration of 5 mg/kg over 1 h followed by a maintenance dose at
50 mg/h, resulting in a total dose of 1450 mg/day in a patient with
body weight of 60 kg. In the recent AVRO study, which used the
same dose as in the ESC Guidelines, the rate of AF conversion to
sinus rhythm by intravenous amiodarone was 5.2% at 90 min and
22.6% at 240 min after amiodarone administration [9]. Although
the total dose used in the present study was lower than that in the
AVRO study, the initial bolus dose was 125 mg for 10 min, and the
infusion rate was higher than that in the AVRO study. The
maintenance dose (48 mg/h for the subsequent 6 h) was similar
to that in the AVRO study. The difference in the method and dose
of bolus administration may be related to the difference in the rate
of sinus rhythm conversion.
Tommaso et al. reported that slowing the heart rate by
intravenous calcium channel blocker administration improves
the hemodynamic state via increased stroke volume and that this
effect may facilitate the conversion to sinus rhythm [10]. In the
present study, there was no signiﬁcant difference between the
mean heart rate just before AF termination in patients with AF
conversion and the mean heart rate at 24 h after amiodarone in
patients without AF conversion.
There have been only a few reports on the rate control effects of
intravenous amiodarone. A previous study showed that a signiﬁ-
cant decrease in heart rate during AF compared to baseline was
noted at 15 min of administration [11]. In a study that compared
rate control effects between bolus administration of amiodarone
and digoxin [12], a signiﬁcant decrease in heart rate was noted at
5 min after amiodarone compared with digoxin. In the present
study, a signiﬁcant decrease in heart rate during AF was noted at
5 h of amiodarone administration in persistent/long-standing
persistent AF, which is indicative of a rate control effect of
intravenous amiodarone. The difference in the timing at which a
signiﬁcant heart rate decrease is obtained after amiodarone may
be related to a difference in patient backgrounds, such as the
presence of AHF in this study. Notably, intravenous amiodarone
never converted AF to sinus rhythm in any of the patients with
persistent/long-standing persistent AF. The effect of intravenous
amiodarone on AF cardioversion in the setting of persistent/long-
standing persistent AF and AHF is thus low.
Recently, the favorable effects of the ultra-short acting beta-
blocker landiolol in preventing AF and/or reducing heart rate
during AF have been demonstrated in several clinical trials [13].
However, there has been no study comparing the rate and rhythm
control effects of landiolol with those of amiodarone. Thus, further
study is needed to establish the rate and rhythm control effects of
landiolol in AF patients with acute decompensated heart failure.
Regarding the inﬂuences of intravenous amiodarone on hemo-
dynamics, we found that blood pressure remained stable, but was
slightly increased in association with a heart rate decrease in some
patients, as reported previously [11]. Furthermore, no serious
adverse effects were noted, and a marked decrease in blood
pressure or bradycardia requiring discontinuation of amiodarone
administration was not observed. Thus, intravenous amiodarone is
safe when used for both rhythm and rate control of AF in the
setting of AHF.
4.4. Limitations
Although this study was performed in a prospective manner,
only 1 arm of amiodarone administration was examined and the
results were not compared with those in a placebo arm. However,
the results clearly demonstrated the rhythm control effects of
amiodarone in recent-onset/transient/paroxysmal AF and the rate
control effects of amiodarone in persistent/long-standing persis-
tent AF complicated by AHF. It may be pointed out that the
number of study patients was too small to conclude that intrave-
nous amiodarone is safe when administered to patients with AHF.
Intravenous amiodarone was reported to be associated with a
decrease in blood pressure and bradycardia. When intravenous
amiodarone is used in patients with AF and AHF, special caution is
required.
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4.5. Conclusions
Intravenous amiodarone is useful in the treatment of AF with
rapid ventricular response in patients with AHF while showing
rhythm and rate control effects. The dosage protocol used for VT/
VF therapy seems to be tolerable in patients with AF and AHF.
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